Company intelligence / Profile preview

Evecxia Therapeutics

Research Triangle Park, North Carolina, United Statesevecxia.com ↗

Ownership: Private
Development stage: Other

Overview

Evecxia has completed Phase 1 trials for both EVX-101 and EVX-301 with favorable safety, tolerability, and pharmacokinetic/pharmacodynamic results. EVX-101 demonstrated the ability to provide sustained and adequate 5-HTP exposure while ensuring safety and tolerability. EVX-301 showed excellent safety and tolerability with evidence of fast-onset brain serotonin activation. A Phase 2 study of adjunctive EVX-101 in depression patients with inadequate response to first-line SSRI/SNRI antidepressants is expected to commence enrollment in late 2024.

Therapeutic areas: Psychiatry
Modalities: Small molecules (5-HTP-based drugs)
Industry: Biotech

Drug pipeline

2 assets

EVX-101

1 more asset in the full pipeline.

Partnerships

Duke University School of MedicineTempusQuotient Sciences

Beyond the preview

Go deeper on Evecxia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evecxia Therapeutics.